Elsevier

The Lancet

Volume 347, Issue 9018, 29 June 1996, Pages 1783-1788
The Lancet

Articles
Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children

https://doi.org/10.1016/S0140-6736(96)91615-3Get rights and content

Abstract

Summary

Background The effects on long-term outcome in childhood acute lymphoblastic leukaemia (ALL) of the duration and the intensity of maintenance chemotherapy need to be assessed reliably. With this objective the Childhood ALL Collaborative Group coordinated a worldwide overview of all randomised trials that began before 1987.

Methods Individual patient data were sought for about 3900 children in trials of longer vs shorter maintenance (eg, 3 vs 2 years), 3700 in trials of intensive "reinduction" chemotherapy during maintenance, and 4400 in trials of various other questions, including 1300 in trials of pulses of vincristine and prednisone (VP) during maintenance. Analyses were of survival in first remission, overall survival, and cause-specific mortality.

Findings Deaths during remission were increased by longer maintenance (2·7% vs 1·2%), VP pulses (4·0 vs 3·2%), and intensive reinduction (4·8% vs 3·3%), but these increases were counterbalanced by reductions in relapses. Total events (relapse or death) were significantly reduced by longer maintenance (23·3% vs 27·6%), VP pulses (31·2% vs40·4%) and intensive reinduction (27·8% vs 35·8%) (each 2p<0·001). Many of those who relapsed were successfully re-treated, however, and only for intensive reinduction was overall survival significantly improved (18·5% vs 22·3%; 2p=0·01).

Interpretation Intensive reinduction chemotherapy in these trials produced an absolute improvement of about 4% in long-term survival; if the extra deaths in remission had been avoided, this would have been a 5% benefit. Further improvements in survival seem more likely to be obtained with intensive treatment than with longer low-level maintenance.

References (36)

  • H. Riehm et al.

    Results and significance of six randomized trials in four consecutive ALL-BFM Studies

    Haem Blood Trans

    (1990)
  • Medical Research Council Working Party on Leukaemia in Childhood

    Treatment of acute lymphoblastic leukaemia: effect of variation in length of treatment on duration of remission

    BMJ

    (1977)
  • Medical Research Council Working Party on Leuklaemia in Childhood

    Effects of varying radiation schedule, cyclophosphamide treatment, and duration of treatment in acute lymphoblastic leukaemia

    BMJ

    (1978)
  • Medical Rsearch Council Working Party on Leukaemia in Childhood

    Duration of chemotherapy in childhood acute lymphoblastic leukaemia

    Med Ped Oncol

    (1982)
  • Jm Chessells et al.

    Medical Research Council Leukaemia Trial—UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukaemia

    J Clin Oncol

    (1986)
  • Wa Bleyer

    Remaining problems in the staging and treatment of childhood lymphoblastic leukemia

    Am J Ped Hem Oncol

    (1989)
  • G. Paolucci et al.

    Treating childhood acute lymphoblastic leukaemia (ALL): Summary often years' experience in Italy

    Med Ped Oncol

    (1989)
  • Cited by (170)

    • Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia

      2021, Blood
      Citation Excerpt :

      Similar to maintenance length, any potential benefit of these therapies is largely based on historical data from older trials when therapy was less intensive and outcomes were poor. Early trials that randomly assigned patients to receive or not receive pulses in maintenance found decreased EFS but similar OS rates and no differences in outcome based on sex.17 Some cooperative groups that successfully eliminated the extra year of maintenance in boys without affecting survival did so using a maintenance backbone that included pulses and IT therapy, whereas others eliminated the extra year of maintenance using a backbone that did not include pulses or IT therapy.

    View all citing articles on Scopus
    1

    Writing committee and participants listed at end of article

    View full text